中国药业
中國藥業
중국약업
CHINA PHARMACEUTICALS
2015年
15期
115-116
,共2页
缩宫素%剂量%新生儿%高胆红素血症%护理干预
縮宮素%劑量%新生兒%高膽紅素血癥%護理榦預
축궁소%제량%신생인%고담홍소혈증%호리간예
oxytocin%dosage%neonatal%hyperbilirubinemia%nursing intervention
目的:探讨产前应用不同剂量缩宫素对新生儿高胆红素血症发生率的影响及护理干预的作用。方法将足月新生儿63例根据产妇产前是否使用缩宫素分为观察组和对照组。观察组33例孕妇接受产前缩宫素注射,最大注射剂量为10 U;对照组30例自然分娩。针对高胆红素血症患儿给予蓝光治疗及足量喂养、无菌操作等护理干预。观察两组新生儿高胆红素血症发病率,并记录胆红素水平,记录新生儿出生1,5 min 后的阿氏评分(Apgar 评分),出生15 min 后的神经行为适应能力( NACS)评分。结果两组新生儿一般资料、NACS 及 Apgar 评分比较,差异无统计学意义。与对照组比较,当缩宫素用量为2.5 U 时,高胆红素血症发病率未见明显统计学差异( P >0.05);当缩宫素用量为5 U 和10 U 时,高胆红素血症发病率显著升高( P <0.05)。护理干预后的总有效率为91.67%,CD4+, CD8+,CD4+/ CD8+百分含量均较干预前升高( P >0.05)。结论在分娩前使用小剂量的缩宫素对新生儿高胆红素血症发生率无明显影响,对新生儿的神经系统和心肺功能无显著损伤。对于分娩过程中使用过缩宫素的新生儿,应出生后立即进行血胆红素动态检测,及时作出相应处理。
目的:探討產前應用不同劑量縮宮素對新生兒高膽紅素血癥髮生率的影響及護理榦預的作用。方法將足月新生兒63例根據產婦產前是否使用縮宮素分為觀察組和對照組。觀察組33例孕婦接受產前縮宮素註射,最大註射劑量為10 U;對照組30例自然分娩。針對高膽紅素血癥患兒給予藍光治療及足量餵養、無菌操作等護理榦預。觀察兩組新生兒高膽紅素血癥髮病率,併記錄膽紅素水平,記錄新生兒齣生1,5 min 後的阿氏評分(Apgar 評分),齣生15 min 後的神經行為適應能力( NACS)評分。結果兩組新生兒一般資料、NACS 及 Apgar 評分比較,差異無統計學意義。與對照組比較,噹縮宮素用量為2.5 U 時,高膽紅素血癥髮病率未見明顯統計學差異( P >0.05);噹縮宮素用量為5 U 和10 U 時,高膽紅素血癥髮病率顯著升高( P <0.05)。護理榦預後的總有效率為91.67%,CD4+, CD8+,CD4+/ CD8+百分含量均較榦預前升高( P >0.05)。結論在分娩前使用小劑量的縮宮素對新生兒高膽紅素血癥髮生率無明顯影響,對新生兒的神經繫統和心肺功能無顯著損傷。對于分娩過程中使用過縮宮素的新生兒,應齣生後立即進行血膽紅素動態檢測,及時作齣相應處理。
목적:탐토산전응용불동제량축궁소대신생인고담홍소혈증발생솔적영향급호리간예적작용。방법장족월신생인63례근거산부산전시부사용축궁소분위관찰조화대조조。관찰조33례잉부접수산전축궁소주사,최대주사제량위10 U;대조조30례자연분면。침대고담홍소혈증환인급여람광치료급족량위양、무균조작등호리간예。관찰량조신생인고담홍소혈증발병솔,병기록담홍소수평,기록신생인출생1,5 min 후적아씨평분(Apgar 평분),출생15 min 후적신경행위괄응능력( NACS)평분。결과량조신생인일반자료、NACS 급 Apgar 평분비교,차이무통계학의의。여대조조비교,당축궁소용량위2.5 U 시,고담홍소혈증발병솔미견명현통계학차이( P >0.05);당축궁소용량위5 U 화10 U 시,고담홍소혈증발병솔현저승고( P <0.05)。호리간예후적총유효솔위91.67%,CD4+, CD8+,CD4+/ CD8+백분함량균교간예전승고( P >0.05)。결론재분면전사용소제량적축궁소대신생인고담홍소혈증발생솔무명현영향,대신생인적신경계통화심폐공능무현저손상。대우분면과정중사용과축궁소적신생인,응출생후립즉진행혈담홍소동태검측,급시작출상응처리。
Objective To observe the effect of oxytocin and nursing intervention applied to the lying - in women during childbirth on the neonatal hyperbilirubinemia. Methods Together 63 full - term healthy newborns were divided into two groups according to maternal pre-natal use of oxytocin, the observation group (using oxytocin, the Max dosage = 10 U) was 33 cases, and the control group (not using oxytocin) was 30 cases. All newborns′ bilirubin levels were detected to calculate the incidence of hyperbilirubinemia. Both of the two groups received the scientific nursing. keep a record on the mean bilirubin, incidence of hyperbilirubinemia and NACS(15 min after) Apgar(1. 5 min after) . Results Both groups didn′t show any differences in the aspect of NACS Apgar aspect. The incidence of hyper-bilirubinemia of the observation group was not higher than that of the control group(2. 5 U, P > 0. 05), the significant when the dosage were 5, 10 U( P < 0. 05). The effection was 91. 67% after treatment, the CD4, CD8, CD4 / CD8 were rised than before treatment( P > 0. 05). Conclusion s Application of oxytocin in regular dose didn′t increase the incidence of neonatal hyperbilirubinemi. The early nursing in-terventions can effectively decrease the incidence of the healthy neonatal hyperbilirubinemia and readmision rate.